Syngene reports second quarter results for FY25

Revenue from operations increases sequentially by 13%

Syngene recognized as one of India’s most sustainable companies by Business World magazine

91st position overall and the only CRDMO featured in the pharmaceutical sector

Syngene wins Asia Pacific Biologics CMO Excellence Awards 2024

Adjudged Best Biologics CMO in South Asia by IMAPAC

Manufacturing the drug substance for Zoetis’ first-in-class mAb osteoarthritis drug

Read Case Study

Syngene achieves silver in EcoVadis ESG assessment

Syngene has been awarded a Silver EcoVadis Medal for FY 2024, placing us among the top 15% of companies assessed.

Read Press Release

Previous slide

Next slide

Syngene reports second quarter results for FY25

Revenue from operations increases sequentially by 13%

Read Press Release

Syngene recognized as one of India’s most sustainable companies by Business World magazine

91st position overall and the only CRDMO featured in the pharmaceutical sector

Syngene wins Asia Pacific Biologics CMO Excellence Awards 2024

Adjudged Best Biologics CMO in South Asia by IMAPAC

Manufacturing the drug substance for Zoetis’ first-in-class mAb osteoarthritis drug

Read Case Study

Syngene achieves silver in EcoVadis ESG assessment

Syngene has been awarded a Silver EcoVadis Medal for FY 2024, placing us among the top 15% of companies assessed.

Read Press Release

Previous slide

Next slide

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

InstaVisit – Visit Syngene virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

View Now

0 +

Active Clients

Collaborations with top 20 Pharma/Biotech companies

5200

Scientists

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents

Latest News

View all

Developing a Complex, First-of-its-kind Antiparasitic Drug for Dogs

News

12th Nov, 2024

Can India Leverage US Biosecure Act to Strengthen CRDMOs?

News

31st Oct, 2024

biologics Roundtable: the current landscape and future developments

News

29th Oct, 2024

Insights

View all

Quantifying a biomarker in mice brain for treating mood and anxiety disorders

A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.

18 October 2024

Risk assessment strategy for nitrosamine drug substance-related impurities

The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.

2 September 2024

Innovation at Syngene: Translatable models for improving cancer research

Syngene has developed orthotopic models validated against the standard of care and tumor models with 3D culture, which can help improve translatability and clinical relevance in cancer research.

12 June 2024

Upcoming events

View all

Biofit 2024

3rd & 4th Dec

Lille, France

Antibody Engineering and Therpeutics USA 2024

15t to 18th Dec

San Diego

Biotech showcase 2025

January 13-15th

San Diego

Partnering at JPM week

January 13-16th

San Diego

SSX India 2025

January 23rd to 25th

India

SCOPE USA 2025

February 3rd-6th

Orlando,Florida

Corporate Social Responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.

Governance

Behind consistent growth is good governance

Careers

Discover a world of opportunities

Annual Reports

Touching a billon lives through innnovation

Discovery

Development

Manufacturing

Discovery

Development & Manufacturing

SynVent Integrated Drug Discovery

Emerging Biopharma

Dedicated Centers

Center for Advanced Protein Studies (CAPS)

Who we are

What we do

Discovery

Development

Manufacturing

Dedicated Centers

InstaVisit – Visit Syngene virtually

Latest News

Developing a Complex, First-of-its-kind Antiparasitic Drug for Dogs

Can India Leverage US Biosecure Act to Strengthen CRDMOs?

biologics Roundtable: the current landscape and future developments

Insights

Quantifying a biomarker in mice brain for treating mood and anxiety disorders

Risk assessment strategy for nitrosamine drug substance-related impurities

Innovation at Syngene: Translatable models for improving cancer research

Upcoming events

Corporate Social Responsibility

Governance

Careers

Annual Reports

Sign-up for our newsletter

Quick links

Business

Get in touch

Other links

To view or email, Please share your details view

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details